These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18953547)

  • 1. Botulinum toxin in paediatric urology: a systematic literature review.
    DasGupta R; Murphy FL
    Pediatr Surg Int; 2009 Jan; 25(1):19-23. PubMed ID: 18953547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin as a new therapy option for voiding disorders: current state of the art.
    Leippold T; Reitz A; Schurch B
    Eur Urol; 2003 Aug; 44(2):165-74. PubMed ID: 12875934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin.
    Gallien P; Robineau S; Verin M; Le Bot MP; Nicolas B; Brissot R
    Arch Phys Med Rehabil; 1998 Jun; 79(6):715-7. PubMed ID: 9630155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of botulinum toxin in the treatment of neurogenic and non-neurogenic voiding dysfunction.
    Smith CP; Somogyi GT; Chancellor MB
    Curr Urol Rep; 2002 Oct; 3(5):382-7. PubMed ID: 12354347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin therapy for neurogenic detrusor overactivity.
    Smaldone MC; Ristau BT; Leng WW
    Urol Clin North Am; 2010 Nov; 37(4):567-80. PubMed ID: 20955908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injectable neuromodulatory agents: botulinum toxin therapy.
    Frenkl TL; Rackley RR
    Urol Clin North Am; 2005 Feb; 32(1):89-99. PubMed ID: 15698881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin in the management of lower urinary tract dysfunction: contemporary update.
    Cruz F; Silva C
    Curr Opin Urol; 2004 Nov; 14(6):329-34. PubMed ID: 15626874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
    Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
    Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
    Karsenty G; Denys P; Amarenco G; De Seze M; Gamé X; Haab F; Kerdraon J; Perrouin-Verbe B; Ruffion A; Saussine C; Soler JM; Schurch B; Chartier-Kastler E
    Eur Urol; 2008 Feb; 53(2):275-87. PubMed ID: 17988791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results.
    Patel AK; Patterson JM; Chapple CR
    Eur Urol; 2006 Oct; 50(4):684-709; discussion 709-10. PubMed ID: 16934391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin for the treatment of lower urinary tract symptoms: a review.
    Sahai A; Khan M; Fowler CJ; Dasgupta P
    Neurourol Urodyn; 2005; 24(1):2-12. PubMed ID: 15578628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
    Gamé X; Mouracade P; Chartier-Kastler E; Viehweger E; Moog R; Amarenco G; Denys P; De Seze M; Haab F; Karsenty G; Kerdraon J; Perrouin-Verbe B; Ruffion A; Soler JM; Saussine C
    J Pediatr Urol; 2009 Jun; 5(3):156-64. PubMed ID: 19264554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urologic applications of botulinum toxin therapy for voiding dysfunction.
    Rackley R; Abdelmalak J
    Curr Urol Rep; 2004 Oct; 5(5):381-8. PubMed ID: 15461917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Botulinum toxin in urology. An inventory].
    Schulte-Baukloh H; Knispel HH
    Urologe A; 2004 Aug; 43(8):963-75. PubMed ID: 15278202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin: a potential alternative to current treatment of neurogenic and idiopathic urinary incontinence due to detrusor overactivity.
    Casanova N; McGuire E; Fenner DE
    Int J Gynaecol Obstet; 2006 Dec; 95(3):305-11. PubMed ID: 17070528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
    Ellsworth P; Travis M
    Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin and refractory non-neurogenic overactive detrusor.
    Ksibi I; Godard AL; Azouvi P; Denys P; Dziri C
    Ann Phys Rehabil Med; 2009 Nov; 52(9):668-83. PubMed ID: 19729357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overactive Bladder Syndrome, Detrusor Overactivity and the Botulinum Toxin.
    Truzzi JC
    Rev Recent Clin Trials; 2015; 10(2):128-34. PubMed ID: 25880125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin injections in the management of non-neurogenic overactive bladders in children.
    Léon P; Jolly C; Binet A; Fiquet C; Vilette C; Lefebvre F; Bouché-Pillon-Persyn MA; Poli-Mérol ML
    J Pediatr Surg; 2014 Sep; 49(9):1424-8. PubMed ID: 25148752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin for conditions of the female pelvis.
    El-Khawand D; Wehbe S; Whitmore K
    Int Urogynecol J; 2013 Jul; 24(7):1073-81. PubMed ID: 23344218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.